Literature DB >> 33799973

Hemorphins Targeting G Protein-Coupled Receptors.

Mohammed Akli Ayoub1,2, Ranjit Vijayan1.   

Abstract

Hemorphins are short peptides produced by the proteolysis of the beta subunit of hemoglobin. These peptides have diverse physiological effects especially in the nervous and the renin-angiotensin systems. Such effects occur through the modulation of a diverse range of proteins including enzymes and receptors. In this review, we focus on pharmacological and functional targeting of G protein-coupled receptors (GPCRs) by hemorphins and their implication in physiology and pathophysiology. Among GPCRs, the opioid receptors constitute the first set of targets of hemorphins with implication in analgesia. Subsequently, several other GPCRs have been reported to be directly or indirectly involved in hemorphins' action. This includes the receptors for angiotensin II, oxytocin, bombesin, and bradykinin, as well as the human MAS-related G protein-coupled receptor X1. Interestingly, both orthosteric activation and allosteric modulation of GPCRs by hemorphins have been reported. This review links hemorphins with GPCR pharmacology and signaling, supporting the implication of GPCRs in hemorphins' effects. Thus, this aids a better understanding of the molecular basis of the action of hemorphins and further demonstrates that hemorphin-GPCR axis constitutes a valid target for therapeutic intervention in different systems.

Entities:  

Keywords:  ACE; AT1R; AngII; GPCR; RAS; hemoglobin; hemorphins; opioid receptors

Year:  2021        PMID: 33799973      PMCID: PMC7998264          DOI: 10.3390/ph14030225

Source DB:  PubMed          Journal:  Pharmaceuticals (Basel)        ISSN: 1424-8247


  65 in total

1.  Comparative effects of angiotensin IV and two hemorphins on angiotensin-converting enzyme activity.

Authors:  Ingrid Fruitier-Arnaudin; Marie Cohen; Stéphanie Bordenave; Frédéric Sannier; Jean-Marie Piot
Journal:  Peptides       Date:  2002-08       Impact factor: 3.750

2.  LVV-hemorphin-7 lowers blood pressure in spontaneously hypertensive rats: radiotelemetry study.

Authors:  J Cejka; B Zelezná; J Velek; J Zicha; J Kunes
Journal:  Physiol Res       Date:  2004       Impact factor: 1.881

3.  Hemorphin and hemorphin-like peptides isolated from dog pancreas and sheep brain are able to potentiate bradykinin activity in vivo.

Authors:  Danielle Ianzer; Katsuhiro Konno; Carlos Henrique Xavier; Reto Stöcklin; Robson Augusto S Santos; Antônio Carlos Martins de Camargo; Daniel Carvalho Pimenta
Journal:  Peptides       Date:  2006-08-09       Impact factor: 3.750

4.  Identification of an antithrombotic allosteric modulator that acts through helix 8 of PAR1.

Authors:  Louisa Dowal; Derek S Sim; James R Dilks; Price Blair; Sarah Beaudry; Bradley M Denker; Georgios Koukos; Athan Kuliopulos; Robert Flaumenhaft
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

5.  Angiotensin IV elevates oxytocin levels in the rat amygdala and produces anxiolytic-like activity through subsequent oxytocin receptor activation.

Authors:  Chad E Beyer; Jason M Dwyer; Brian J Platt; Sarah Neal; Bin Luo; Huai-Ping Ling; Qian Lin; Robert J Mark; Sharon Rosenzweig-Lipson; Lee E Schechter
Journal:  Psychopharmacology (Berl)       Date:  2010-03-12       Impact factor: 4.530

Review 6.  Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development.

Authors:  Katie O'Callaghan; Athan Kuliopulos; Lidija Covic
Journal:  J Biol Chem       Date:  2012-02-28       Impact factor: 5.157

7.  The globin fragment LVV-hemorphin-7 is an endogenous ligand for the AT4 receptor in the brain.

Authors:  I Moeller; R A Lew; F A Mendelsohn; A I Smith; M E Brennan; T J Tetaz; S Y Chai
Journal:  J Neurochem       Date:  1997-06       Impact factor: 5.372

8.  Identification and functional characterization of hemorphins VV-H-7 and LVV-H-7 as low-affinity agonists for the orphan bombesin receptor subtype 3.

Authors:  Hans-Peter Lammerich; Annette Busmann; Christian Kutzleb; Martin Wendland; Petra Seiler; Claudia Berger; Peter Eickelmann; Markus Meyer; Wolf-Georg Forssmann; Erik Maronde
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

9.  Hemorphin 7 reflects hemoglobin proteolysis in abdominal aortic aneurysm.

Authors:  Tiphaine Dejouvencel; Delphine Féron; Patrick Rossignol; Marc Sapoval; Claude Kauffmann; Jean-Marie Piot; Jean-Baptiste Michel; Ingrid Fruitier-Arnaudin; Olivier Meilhac
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-11-12       Impact factor: 8.311

10.  Mechanism of intracellular allosteric β2AR antagonist revealed by X-ray crystal structure.

Authors:  Xiangyu Liu; Seungkirl Ahn; Alem W Kahsai; Kai-Cheng Meng; Naomi R Latorraca; Biswaranjan Pani; A J Venkatakrishnan; Ali Masoudi; William I Weis; Ron O Dror; Xin Chen; Robert J Lefkowitz; Brian K Kobilka
Journal:  Nature       Date:  2017-08-16       Impact factor: 49.962

View more
  5 in total

1.  Investigation of the structure-activity relationship in a series of new LVV- and VV-hemorphin-7 analogues designed as potential anticonvulsant agents.

Authors:  Petar Todorov; Stela Georgieva; Petia Peneva; Jana Tchekalarova
Journal:  Amino Acids       Date:  2022-01-03       Impact factor: 3.520

Review 2.  Mass Spectrometry Approaches Empowering Neuropeptide Discovery and Therapeutics.

Authors:  Krishna D B Anapindi; Elena V Romanova; James W Checco; Jonathan V Sweedler
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

3.  Special Issue "GPCRs: Ligands and beyond 2022".

Authors:  Erika Cione; Maria Cristina Caroleo
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-24

4.  Synthesis of New Modified with Rhodamine B Peptides for Antiviral Protection of Textile Materials.

Authors:  Petar Todorov; Stela Georgieva; Desislava Staneva; Petia Peneva; Petar Grozdanov; Ivanka Nikolova; Ivo Grabchev
Journal:  Molecules       Date:  2021-10-31       Impact factor: 4.411

Review 5.  Hemorphins-From Discovery to Functions and Pharmacology.

Authors:  Przemyslaw Mielczarek; Kinga Hartman; Anna Drabik; Hao-Yuan Hung; Eagle Yi-Kung Huang; Ewa Gibula-Tarlowska; Jolanta H Kotlinska; Jerzy Silberring
Journal:  Molecules       Date:  2021-06-25       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.